Targeted photoimmunotherapy for cancer

Area of Science:

• Biomedical Engineering
• Oncology
• Photochemistry

Background:

• Photodynamic therapy (PDT) is an approved cancer treatment utilizing photosensitizers and light to generate cytotoxic reactive oxygen species.
• PDT effectively induces tumor cell death, damages tumor vasculature, and promotes inflammation.
• A key limitation of traditional PDT is the lack of selectivity for malignant tissues over healthy ones.

Purpose of the Study:

• To enhance the targeting precision of photosensitizing agents in photodynamic therapy.
• To explore the theranostic potential of antibody-conjugated photosensitizers.

Main Methods:

• Development of antibody-conjugated photosensitizing molecules.
• Administration of these conjugates for targeted delivery to malignant sites.
• Utilizing the fluorescence emission properties of the conjugates.

Main Results:

• Antibody conjugation significantly improved the selectivity of photosensitizers for malignant tissues.
• Targeted delivery of photosensitizers was achieved with unprecedented precision.
• The developed supramolecular species demonstrated intrinsic theranostic capabilities.

Conclusions:

• Antibody-conjugated photosensitizers represent a significant advancement in targeted photodynamic therapy.
• These theranostic agents offer improved efficacy and precision in cancer treatment.
• The dual capability for therapy and diagnosis opens new avenues in oncology.